Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073071 | 0.85 | PARP1 (0.50) | PARP1ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL14072965 | 0.81 | GAA (0.63) | ALDH1A1MAPTGAATSHR | |
| SCHEMBL9130576 | 0.80 | PARP1 (0.60) | PARP1ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL14073116 | 0.79 | PARP1 (0.62) | PARP1ALDH1A1MAPTTSHRHPGD | |
| SCHEMBL14073370 | 0.79 | HPGD (0.64) | PARP1ALDH1A1MAPTSMN1; SMN2TSHR | |
| SCHEMBL14073372 | 0.78 | KMT2A (0.54) | PARP1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL4295364 | 0.78 | PARP1 (0.65) | PARP1ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL14073095 | 0.78 | MAPT (0.60) | PARP1ALDH1A1MAPTTSHRKMT2A | |
| SCHEMBL14073059 | 0.77 | GAA (0.59) | PARP1ALDH1A1MAPTGAA | |
| SCHEMBL4286655 | 0.77 | PARP1 (0.67) | PARP1ALDH1A1MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | PARP1 327/4885ALDH1A1 714/4885MAPT 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.